On March 26, 2018, BOC Sciences, one of the world’s leading chemical suppliers, announced to add a new technology called DNA-encoded library technology (DEL) for researchers in hope of facilitating their drug discovery efforts. Drug development has long been viewed as a lengthy, complex, and costly process that bares little chances to succeed all the way to the end.
DNA-encoded library is a new screening platform commonly used to discover small molecules that interfere with the activity of pharmaceutically relevant proteins. Along with high-throughput screening, it has become a widely accepted method for hit finding in the past two decades. DNA-encoded chemical libraries are hybrid-type collections of combinatorial organic molecules, individually coupled to distinctive DNA fragments.
“The DEL techonology platform integrates synthesis of DNA-encoded libraries, affinity selection against a target of interest, DNA sequencing, data translation, off-DNA compound synthesis and evaluation of off- DNA compounds for activity into a multicomponent process for ligand discovery,” revealed Mr. Barron Jones, the Marketing Executive of BOC Sciences.
DNA-encoded library technology has been shown to be useful by the numerous, valuable hits that have been published as well as by the announcement of several drug development candidates that originated from DELT hits. “In theory, this method is readily applicable to any hit finding problem for soluble protein targets. The robust nature of DNA binding and recognition properties is part of the continuous evolution of DNA-encoded and DNA-directed methods,” further added Mr. Barron Jones. “With our advanced technology and reputable professionalism, we believe this new platform of our company would be of great help for those who are devoted to drug discovery.”
About Drug Discovery
The discovery of a novel drug is usually a multi-phase process, and one of central steps in drug discovery is the identification of binding molecules to protein targets of pharmaceutical interest. Some methods including high-throughput screening (HTS), fragment-based drug discovery, and computer-assisted drug discovery are available for early drug hit discovery. The molecular diversity and quality of the screening collection can be crucial in using HTS to discover compounds having desirable pharmacological properties. Biological selection methods are largely relied on the expression and screening of peptides and proteins that are encoded by DNA and expressed by a cell, so the construction and screening of libraries containing billions of polypeptides could largely facilitate biology-based drug discovery.
About BOC Sciences
In the last decade and more, BOC Sciences has long been supplying a wide collection of products ranging from inhibitors, metabolites to natural compounds, stem cell molecules. With the expansion of businesses, BOC Sciences launched a string of services like isotope labeling and chiral synthesis, and it continues to introduce more services and platforms in an effort to accelerate the R&D process in drug discovery.
Company Name: BOC Sciences
Contact Person: Linna Green
Email: Send Email
Phone: 0631 619 7922
Address:45-16 Ramsey Road
State: NY 11967
Country: United States